Effects of CYP2C19 variants on the metabolism of tapentadol in vitro

被引:1
|
作者
Xu, Ren-ai [1 ]
Fang, Ping [2 ]
Ye, Zhize [3 ]
Han, Mingming [3 ]
Cai, Jian-Ping [4 ]
Hu, Guo-Xin [3 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China
[4] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol,Natl Hlth Commiss, Key Lab Geriatr,Beijing Inst Geriatr,Inst Geriatr, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
Cytochrome P450; Drug metabolism; Genetic polymorphism; Tapentadol; FUNCTIONAL-CHARACTERIZATION; GENETIC-POLYMORPHISM; ALLELIC VARIANTS; PHARMACOLOGY; POPULATION; TRAMADOL; ENZYMES; 2C19;
D O I
10.22038/IJBMS.2022.56996.12710
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective(s): This study aims to evaluate the catalytic activities of 31 CYP2C19 alleles and their effects on the metabolism of tapentadol in vitro. Materials and Methods: Insect microsomes expressing the CYP2C19 alleles were incubated with 50- 1250 mu M tapentadol for 40 min at 37 degrees C and terminated by cooling to -80 degrees C, immediately. Tapentadol and N-desmethyl tapentadol were analyzed by a UPLC-MS/MS system. The kinetic parameters Km, Vmax, and intrinsic clearance (Vmax/Km) of N-desmethyl tapentadol were determined. Results: As a result, the intrinsic clearance (Vmax/Km) values of most variants were significantly altered, while CYP2C19.3 and 35FS had no detectable enzyme activity. Only one variant, N277K, showed no significant difference from CYP2C19.1B. Two variants CYP2C19.29 and L16F displayed markedly increased intrinsic clearance values of 302.22% and 199.97%, respectively; whereas 24 variants exhibited significantly decreased relative clearance ranging from 0.32% to 79.15% of CYP2C19.1B. Especially, CYP2C19.2G, 2H, R124Q, and R261W exhibited a drastic decrease in clearance (>80%) compared with wild-type CYP2C19.1B. Conclusion: As the first study of all aforementioned alleles for tapentadol metabolism, the comprehensive data in vitro may provide novel insights into the allele-specific and substrate-specific activity of CYP2C19.
引用
收藏
页码:659 / 663
页数:5
相关论文
共 50 条
  • [21] Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    Lee, Choong-Min
    Jung, Eui-Hyun
    Chae, Won-Ki
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2018, 41 (08) : 861 - 866
  • [22] In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19)
    Pan, Yan
    Abd-Rashid, Badrul Amini
    Ismail, Zakiah
    Ismail, Rusli
    Mak, Joon Wah
    Pook, Peter C. K.
    Er, Hui Meng
    Ong, Chin Eng
    JOURNAL OF ETHNOPHARMACOLOGY, 2011, 133 (02) : 881 - 887
  • [23] Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina
    Akasaka, Tomonori
    Sueta, Daisuke
    Arima, Yuichiro
    Tabata, Noriaki
    Takashio, Seiji
    Izumiya, Yasuhiro
    Yamamoto, Eiichiro
    Yamamuro, Megumi
    Tsujita, Kenichi
    Kojima, Sunao
    Kaikita, Koichi
    Kajiwara, Ayami
    Morita, Kazunori
    Oniki, Kentaro
    Saruwatari, Junji
    Nakagawa, Kazuko
    Ogata, Yasuhiro
    Matsui, Kunihiko
    Hokimoto, Seiji
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2016, 311 (06): : H1409 - H1415
  • [24] A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters
    Kanjanasilp, Juntip
    Sawangjit, Ratree
    Phanthaisong, Sirikhwan
    Borihanthanawuth, Wongvaruth
    PHARMACOGENOMICS, 2021, 22 (10) : 629 - 640
  • [25] Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem
    Ji-Yeong Byeon
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Eui-Hyun Jung
    Won-Ki Chae
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2018, 41 : 861 - 866
  • [26] A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry
    Bathum, L
    Hansen, TS
    Horder, M
    Brosen, K
    THERAPEUTIC DRUG MONITORING, 1998, 20 (01) : 1 - 6
  • [27] Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants
    Kelly, Ronan P.
    Close, Sandra L.
    Farid, Nagy A.
    Winters, Kenneth J.
    Shen, Lei
    Natanegara, Fanni
    Jakubowski, Joseph A.
    Ho, Mary
    Walker, Joseph R.
    Small, David S.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (01) : 93 - 105
  • [28] The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine
    Nakhonsri, Vorthunju
    John, Shobana
    Panumasmontol, Hathaichanok
    Jantorn, Manassanan
    Chanthot, Pongpipat
    Hanpramukkun, Nuntachai
    Meelarp, Supaporn
    Sukasem, Chonlaphat
    Tongsima, Sissades
    Hasatsri, Sukhontha
    Prawang, Abhisit
    Thaingtamtanha, Thanawat
    Vanwong, Natchaya
    Atasilp, Chalirmporn
    Chamnanphon, Monpat
    Jinda, Pimonpan
    Satapornpong, Patomsong
    APPLICATION OF CLINICAL GENETICS, 2024, 17 : 96 - 106
  • [29] Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778
    Cheng, Yaofeng
    Wang, Lifei
    Iacono, Lisa
    Zhang, Donglu
    Chen, Weiqi
    Gong, Jiachang
    Humphreys, William Griffith
    Gan, Jinping
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (01) : 130 - 141
  • [30] Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele
    Pedersen, Rasmus S.
    Noehr-Jensen, Lene
    Brosen, Kim
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2013, 40 (10): : 683 - 688